Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock: Insider Bros. Advisors Lp Baker Acquires 76,140 Shares

Key Points

• Director Bros. Advisors Lp Baker bought 76,140 shares at an average price of $384.32, spending about $29.3 million and increasing the position by 3.88%. The director also bought 15,666 shares earlier that week.
• Madrigal reported quarterly EPS of $1.83, beating the consensus estimate of a $1.09 loss, while revenue of $431.3 million topped expectations of $404.2 million.
• Analyst sentiment is largely positive, with a “Moderate Buy” consensus and an average price target of $706.87; however, law firms have announced investigations related to the quarterly filing, which could add uncertainty.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Bros. Advisors Lp Baker acquired 76,140 shares of the business's stock in a transaction dated Friday, November 6th. The stock was purchased at an average cost of $384.32 per share, for a total transaction of $29,262,124.80. Following the completion of the acquisition, the director directly owned 2,040,682 shares of the company's stock, valued at approximately $784,274,906.24. This trade represents a 3.88% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Wednesday, November 4th, Bros. Advisors Lp Baker acquired 15,666 shares of Madrigal Pharmaceuticals stock. The stock was acquired at an average cost of $367.71 per share, for a total transaction of $5,760,544.86.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ:MDGL traded down $0.47 during midday trading on Friday, reaching $399.63. The company's stock had a trading volume of 1,087,445 shares, compared to its average volume of 352,856. The firm has a market capitalization of $9.28 billion, a PE ratio of -66.83 and a beta of -0.98. Madrigal Pharmaceuticals, Inc. has a twelve month low of $353.54 and a twelve month high of $615.00. The stock has a fifty day moving average of $489.63 and a 200 day moving average of $497.94. The company has a quick ratio of 2.94, a current ratio of 3.05 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to the consensus estimate of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. During the same period in the previous year, the firm posted ($5.08) earnings per share. On average, equities analysts expect that Madrigal Pharmaceuticals, Inc. will post -6.88 EPS for the current fiscal year.

Madrigal Pharmaceuticals News Roundup

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MDGL. Barclays reduced their price objective on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an "overweight" rating for the company in a research report on Monday, August 3rd. HC Wainwright began coverage on shares of Madrigal Pharmaceuticals in a research note on Wednesday. They set a "strong-buy" rating for the company. UBS Group restated a "buy" rating and set a $735.00 price target on shares of Madrigal Pharmaceuticals in a research report on Wednesday, October 14th. Canaccord Genuity Group raised their price target on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $706.87.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC lifted its stake in Madrigal Pharmaceuticals by 27.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company's stock worth $1,051,727,000 after acquiring an additional 433,804 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth about $1,039,650,000. Paulson & CO. Inc. purchased a new position in shares of Madrigal Pharmaceuticals in the second quarter valued at approximately $719,524,000. BlackRock Inc. purchased a new position in shares of Madrigal Pharmaceuticals in the second quarter valued at approximately $644,753,000. Finally, Wellington Management Group LLP boosted its stake in shares of Madrigal Pharmaceuticals by 18.8% in the second quarter. Wellington Management Group LLP now owns 825,714 shares of the biopharmaceutical company's stock valued at $443,367,000 after purchasing an additional 130,756 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal's lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.